Imatinib mesylate is an anti-cancer agent that competitively inhibits several receptor tyrosine kinases (RTKs). RTKs play important roles in the regulation of primordial follicle formation, the recruitment of primordial follicles into the pool of growing follicles and maturation of the follicles. In the present study, we investigated the effects of the tyrosine kinase inhibitor imatinib on primordial follicle assembly and early folliculogenesis in postnatal rats. Female Sprague-Dawley rats were treated with either imatinib (150mg/kg) or placebo (water) on postnatal days 2-4. Bilateral ovariectomy was performed on postnatal day 2 and 5. Histology, immunohistochemistry, and mRNA analysis were performed. Imatinib treatment was associated with ...
To clarify the development of follicular growth and atresia in the immature ovary, rats. ovaries and...
Is the c-Jun-N-terminal kinase (JNK) pathway implicated in primordial follicle activation?Culture of...
AbstractImatinib mesylate, a selective tyrosine kinase inhibitor, is the first line treatment agains...
Imatinib mesylate is an anti-cancer agent that competitively inhibits several receptor tyrosine kina...
Chemotherapy may result in ovarian atrophy, a depletion of the primordial follicle pool, diminished ...
Objective: The impact of imatinib, a tyrosine kinase inhibitor, on ovarian follicles and several pro...
Imatinib should be avoided in women planning to become pregnant or during pregnancy, due to a higher...
Chemotherapy treatment in premenopausal women has been linked to ovarian follicle loss and premature...
Chemotherapy treatment in premenopausal women has been linked to ovarian follicle loss and premature...
The current study was designed to investigate the actions of Anti-Müllerian Hormone (AMH) on primord...
WOS: 000230814700003PubMed ID: 15089860Aim: To determine the effect of paclitaxel and cisplatin in t...
At, or around, birth female mammals are already endowed with a finite stock of oocytes. The majorit...
Kit Ligand (KL), one of the first growth factors in ovarian follicle, plays a key role in mammalian ...
The current study was designed to investigate the actions of Anti-Müllerian Hormone (AMH) on primor...
The purpose of this study was to characterize the patterns of ovarian cell proliferation during the ...
To clarify the development of follicular growth and atresia in the immature ovary, rats. ovaries and...
Is the c-Jun-N-terminal kinase (JNK) pathway implicated in primordial follicle activation?Culture of...
AbstractImatinib mesylate, a selective tyrosine kinase inhibitor, is the first line treatment agains...
Imatinib mesylate is an anti-cancer agent that competitively inhibits several receptor tyrosine kina...
Chemotherapy may result in ovarian atrophy, a depletion of the primordial follicle pool, diminished ...
Objective: The impact of imatinib, a tyrosine kinase inhibitor, on ovarian follicles and several pro...
Imatinib should be avoided in women planning to become pregnant or during pregnancy, due to a higher...
Chemotherapy treatment in premenopausal women has been linked to ovarian follicle loss and premature...
Chemotherapy treatment in premenopausal women has been linked to ovarian follicle loss and premature...
The current study was designed to investigate the actions of Anti-Müllerian Hormone (AMH) on primord...
WOS: 000230814700003PubMed ID: 15089860Aim: To determine the effect of paclitaxel and cisplatin in t...
At, or around, birth female mammals are already endowed with a finite stock of oocytes. The majorit...
Kit Ligand (KL), one of the first growth factors in ovarian follicle, plays a key role in mammalian ...
The current study was designed to investigate the actions of Anti-Müllerian Hormone (AMH) on primor...
The purpose of this study was to characterize the patterns of ovarian cell proliferation during the ...
To clarify the development of follicular growth and atresia in the immature ovary, rats. ovaries and...
Is the c-Jun-N-terminal kinase (JNK) pathway implicated in primordial follicle activation?Culture of...
AbstractImatinib mesylate, a selective tyrosine kinase inhibitor, is the first line treatment agains...